X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
humans (22) 22
female (17) 17
oncology (12) 12
adult (11) 11
cancer (11) 11
male (11) 11
middle aged (11) 11
aged (9) 9
mutation (9) 9
breast neoplasms - genetics (6) 6
genetic aspects (6) 6
polymorphism, single nucleotide (6) 6
research (6) 6
breast neoplasms - drug therapy (5) 5
germ-line mutation (5) 5
paclitaxel (5) 5
pharmacokinetics (5) 5
risk factors (5) 5
treatment outcome (5) 5
tumors (5) 5
aged, 80 and over (4) 4
analysis (4) 4
association (4) 4
breast cancer (4) 4
genetic predisposition to disease (4) 4
genetic variation (4) 4
genetics & heredity (4) 4
identification (4) 4
kidney neoplasms - genetics (4) 4
medical and health sciences (4) 4
medicin och hälsovetenskap (4) 4
mutations (4) 4
neurotoxicity (4) 4
paraganglioma - genetics (4) 4
pharmacology & pharmacy (4) 4
pheochromocytoma - genetics (4) 4
adrenal gland neoplasms - genetics (3) 3
alleles (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
carcinoma, renal cell - genetics (3) 3
care and treatment (3) 3
chemotherapy (3) 3
children (3) 3
clinical medicine (3) 3
cytochrome p-450 cyp3a - genetics (3) 3
dead-box rna helicases - genetics (3) 3
diagnosis (3) 3
disease-free survival (3) 3
drug therapy (3) 3
everolimus (3) 3
gene expression (3) 3
gene expression regulation, neoplastic (3) 3
genome-wide association (3) 3
health aspects (3) 3
klinisk medicin (3) 3
paclitaxel - adverse effects (3) 3
patients (3) 3
peripheral nervous system diseases - chemically induced (3) 3
peripheral nervous system diseases - genetics (3) 3
peripheral neuropathy (3) 3
pharmacogenetics (3) 3
pheochromocytoma (3) 3
research article (3) 3
ribonuclease iii - genetics (3) 3
sequence analysis, dna (3) 3
survival (3) 3
survival rate (3) 3
usage (3) 3
adolescent (2) 2
adrenal gland neoplasms - diagnosis (2) 2
amino acid sequence (2) 2
amodiaquine (2) 2
animals (2) 2
antineoplastic agents, phytogenic - adverse effects (2) 2
antineoplastic agents, phytogenic - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
biomarkers, tumor - genetics (2) 2
biotechnology & applied microbiology (2) 2
breast (2) 2
breast neoplasms - complications (2) 2
carcinoma, renal cell - drug therapy (2) 2
chromosomes (2) 2
cyp2c8 (2) 2
cyp3a4 (2) 2
cytochrome p-450 cyp2c8 - genetics (2) 2
deoxyribonucleic acid--dna (2) 2
dose-response relationship, drug (2) 2
down-regulation (2) 2
endocrinology & metabolism (2) 2
exome (2) 2
exons (2) 2
families & family life (2) 2
gene mutations (2) 2
genes (2) 2
genetic polymorphisms (2) 2
genetics (2) 2
genotype (2) 2
genotyping (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 03/2017, Volume 23, Issue 5, pp. 1227 - 1235
Purpose: Neuropathy is the dose-limiting toxicity of paclitaxel and a major cause for decreased quality of life. Genetic factors have been shown to contribute... 
BREAST-CANCER | ONCOLOGY | TYROSINE KINASE | CORTICOSPINAL TRACT | RECEPTOR | INDUCED NEUROTOXICITY | SENSORY NEUROPATHY | KNOCKOUT MICE | IDENTIFICATION | GENOME-WIDE ASSOCIATION | CYP2C8-ASTERISK-3 | Receptor, EphA5 - genetics | Biomarkers, Pharmacological - analysis | Peripheral Nervous System Diseases - chemically induced | Genetic Association Studies | Humans | Middle Aged | Proportional Hazards Models | Paclitaxel - adverse effects | Receptor, EphA8 - genetics | Ovarian Neoplasms - complications | Breast Neoplasms - drug therapy | Breast Neoplasms - complications | Receptor, EphA6 - genetics | Quality of Life | Adult | Female | Aged | Peripheral Nervous System Diseases - pathology | Polymorphism, Single Nucleotide | Paclitaxel - administration & dosage | Peripheral Nervous System Diseases - genetics | Ovarian Neoplasms - drug therapy | Drugs | Toxicity | Genes | Risk | Peripheral neuropathy | Gene sequencing | Confidence intervals | Regression models | Neurotoxicity | Coding | Quality | Charcot-Marie-Tooth disease | Paclitaxel | Genetic factors | Statistical analysis | Markers | Pharmacology | Regression analysis | Patients | Quality of life | Genetic markers | Gene frequency | Experimental design | Pharmacokinetics | Cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal Article
Journal of Medical Genetics, ISSN 0022-2593, 10/2015, Volume 52, Issue 10, pp. 647 - 656
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2015, Volume 107, Issue 5, p. 1
Journal Article
Journal of Molecular Diagnostics, ISSN 1525-1578, 07/2017, Volume 19, Issue 4, pp. 575 - 588
Genetic diagnosis is recommended for all pheochromocytoma and paraganglioma (PPGL) cases, as driver mutations are identified in approximately 80% of the cases.... 
Paraganglioma - genetics | Pheochromocytoma - diagnosis | Humans | Middle Aged | Male | Paraganglioma - diagnosis | DNA Mutational Analysis - methods | Adrenal Gland Neoplasms - diagnosis | Genetic Variation | Adult | Female | Pheochromocytoma - genetics | Mutation | High-Throughput Nucleotide Sequencing - methods | Adrenal Gland Neoplasms - genetics | Regular
Journal Article
Journal of Molecular Medicine-JMM, ISSN 0946-2716, 2015, Volume 93, Issue 11, pp. 1247 - 1255
Journal Article
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2015, Volume 107, Issue 5, p. 1
  Disruption of the Krebs cycle is a hallmark of cancer. IDH1 and IDH2 mutations are found in many neoplasms, and germline alterations in SDH genes and FH... 
Enzymes | Mutation | Gene expression | Deoxyribonucleic acid--DNA | Cancer | Tumors
Journal Article
BMC Cancer, ISSN 1471-2407, 05/2018, Volume 18, Issue 1, pp. 561 - 5
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, pp. e0180192 - e0180192
Purpose Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that... 
PLUS EXEMESTANE | THERAPY | CALCINEURIN-INHIBITORS | BOLERO-2 | PATHWAY | MULTIDISCIPLINARY SCIENCES | RESISTANCE | MTOR INHIBITORS | SINGLE-NUCLEOTIDE POLYMORPHISMS | PROGRESSION | TRANSPLANTATION | Pharmacogenetics | Prognosis | Humans | Middle Aged | Genotype | Survival Rate | Treatment Outcome | Antineoplastic Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Everolimus - pharmacokinetics | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Everolimus - adverse effects | Adult | Breast Neoplasms - mortality | Everolimus - therapeutic use | Female | Aged | Antineoplastic Agents - pharmacokinetics | Polymorphism, Single Nucleotide | Physiological aspects | Breast cancer | Genetic aspects | Research | Drug therapy | Pharmacokinetics | Genetic polymorphisms | TOR protein | Transplants & implants | Toxicity | Genes | AKT protein | Oncology | Biochemistry | Single-nucleotide polymorphism | Metastasis | Cancer therapies | Blood | Metastases | Hyperglycemia | Aromatase | Genetics | Drug dosages | Medical research | Pharmacodynamics | Mucositis | Hematology | Endocrine therapy | Pharmacology | Patients | Survival | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Post-menopause | Blood levels | Chemotherapy | Infectious diseases | Pneumonitis | Womens health | Medical prognosis | Alleles | Breast | Replication | Plasma levels | Carrier density | Tumors | Cancer | Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. e784 - e792
Background Peripheral neuropathy is the dose‐limiting toxicity of many oncology drugs, including paclitaxel. There is large interindividual variability in the... 
Comorbidities | Peripheral neuropathy | Risk factors | Concomitant medications | Paclitaxel | TAXANE-INDUCED NEUROPATHY | ACETYL-L-CARNITINE | VARIANTS | CANCER | NEUROTOXICITY | BREAST | WOMEN | ONCOLOGY | ASSOCIATION | POLYPHARMACY | Index Medicus
Journal Article